NL-OMON36078已完成不适用
An open-label, two period study to determine the excretion balance and pharmacokinetics of 14C-GSK573719, administered as single dose of an oral solution and an intravenous infusion, to healthy male adults - 14C-GSK573719 ADME study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy male subjects
- •non smokers
- •Age: 30-55 years
- •BMI: 18.5-29.0 kg/m2
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1 liter of blood in the 10 months prior the start of this study.
研究者
相似试验
招募中
4 期
Probiotics for prevention of necrotising enterocoilitis in preterm neonates.CTRI/2018/01/011079Department of Pediatrics Bhavnagar
已完成
不适用
An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteersCOPD10024970AsthmaNL-OMON34294GlaxoSmithKline6
已完成
不适用
One-sequence, two-period, open-label study to evaluate the effects of FTY720 on the pharmacokinetics of an oral contraceptive (levonorgestrel/ethinyl estradiol) in healthy female volunteers.multiple sclerose10012303MSNL-OMON35177ovartis31
进行中（未招募）
不适用
An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone deficiency.AGHD Adult Growth Hormone DeficiencyEUCTR2005-001658-25-BEPfizer Global Research and Development8
进行中（未招募）
不适用
Two-period, single-dose pharmacokinetic study in male adolescent patients with Fragile X Syndrome (FXS).Fragile X SyndromeMedDRA version: 14.0Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-019353-18-Outside-EU/EEAovartis Pharma Services AG12